Intragastric immunization of mice with enterohemorrhagic Escherichia coli O157:H7 bacterial ghosts reduces mortality and shedding and induces a Th2-type dominated mixed immune response
Intragastric immunization of mice with enterohemorrhagic Escherichia coli O157:H7 bacterial ghosts reduces mortality and shedding and induces a Th2-type dominated mixed immune response
复制标题
用肠出血性大肠杆菌 O157:H7 菌影对小鼠进行胃内免疫可降低死亡率和脱落率，并诱导 Th2 型主导的混合免疫反应
DOI：
10.1139/w10-025
复制
发表时间：
2010-05-01
影响因子：
2.8
通讯作者：
Wang, Hui
中科院分区：
文献类型：
--
作者：
Cai, Kun;Gao, Xiang;Wang, Hui
以细菌血影（BG）为基础的肠出血性大肠杆菌O 157：H7感染疫苗的开发。本研究的目的是评价E. coli O 157：H7 BGs在小鼠模型中的表达，并揭示其免疫应答机制。加强免疫的保护率（84%）高于单剂免疫（56%）。灌胃免疫E. coliO 157：H7 BGs诱导体液免疫和细胞免疫应答。CD 4（+）T细胞的增殖反应是由抗原提呈细胞介导的。体液免疫反应占主导地位，而细胞免疫反应发展较晚。Th 1/Th 2混合免疫反应平衡炎症反应。抑制作用证实了免疫血清的抗粘附作用，可抑制90%以上的大肠杆菌粘附。coli O 157：H7对Hep-2靶细胞的体外杀伤作用。特异性抗内皮素抗体滴度，内皮素是一种重要的粘附分子。coli O 157：H7对靶细胞的免疫反应与特异性免疫球蛋白A或G抗体滴度相关。因此，将来对BG疫苗进行临床试验是可行的。
A bacterial ghost (BG)-based vaccine was developed against enterohemorrhagic Escherichia coli O157:H7 infection. The aim of this study was to evaluate the protective effect of E. coli O157:H7 BGs in a mouse model and to reveal the mechanism of the immune response. Booster immunization provided a higher protection rate (84%) than single-dose immunization (56%). Intragastric immunization of E. coli O157:H7 BGs induced both humoral and cellular immune responses. The proliferative response of CD4(+) T cells was mediated by the antigen-presenting cells. The humoral immune response dominated the immune response, while the cellular immune response developed later. Inflammatory reaction was balanced by the mixed Th1/Th2 immune response. The immune sera anti-adhesion effect was confirmed by the inhibition effect, which could inhibit >90% of the adhesion of E. coli O157:H7 to Hep-2 target cells in vitro. Antibody titer specific for intimin, a molecule important for adhesion of E. coli O157:H7 to target cells, correlated with specific immunoglobulin A or G antibody titer. Therefore, it might be feasible to clinically test BG vaccines in the future.